Savient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates....

|About: Savient Pharmaceuticals, Inc. (SVNTQ)|By:, SA News Editor

Savient Pharmaceuticals (SVNT -11%) takes a hit today after its Q1 results missed estimates. Total revenue actually jumped nearly 170% Y/Y, but bottom line margins were hit as expenses increased sharply. Much of the increase in expenses had to do with the commercialization and marketing of its new gout drug Krystexxa.